Background: Novel oral anticoagulants (NOACs) have shown to be both safe and effective
for ischemic stroke prevention in patients with nonvalvular atrial fibrillation (NVAF). We …

Purpose Patients with Atrial Fibrillation (AF) and prior stroke are classified as high risk in all
risk stratification schemes. A systematic review and meta-analysis was performed to …

Background Stroke is the most serious clinical consequence of atrial fibrillation, which is the
most common cardiac arrhythmia. Non-vitamin K antagonist oral anticoagulants (NOACs) …

Background Four nonvitamin K antagonist oral anticoagulants (NOACs) are approved for
stroke prevention in patients with nonvalvular atrial fibrillation (NVAF). Aims In this review …

Background Much direct evidence has proved that the novel oral anticoagulants (NOACs)
are noninferior or superior to warfarin for stroke prevention in patients with nonvalvular atrial …

BACKGROUND Warfarin reduces stroke in patients with atrial fibrillation. However, its
narrow therapeutic index and need for chronic monitoring are barriers to its optimal …

Objectives To critically appraise published network meta-analyses (NMAs) evaluating the
efficacy or safety of the new oral anticogulants (NOACs) dabigatran, rivaroxaban, and …

Background and Purpose—Evidence from the real-world setting complements evidence
coming from randomized controlled trials. We aimed to summarize all available evidence …

Background: To review data from the pivotal phase III trials evaluating the efficacy and safety
of direct oral anticoagulants (DOACs) versus warfarin for stroke prevention in patients with …

Background and Purpose—This ARISTOPHANES study (Anticoagulants for Reduction in
Stroke: Observational Pooled Analysis on Health Outcomes and Experience of Patients) …